1型糖尿病器官捐献者胰岛细胞中肠道病毒VP1蛋白与HLA I类分子高表达
基于nPOD 188例器官捐献者胰腺等组织,评估肠道病毒衣壳蛋白VP1与胰岛HLA I类分子高表达的关系。T1D-ICI供者胰岛VP1阳性率77.5%高于ND供者38.2%(p<0.001),VP1阳性与HLA-I高表达相关;所有供者合并分析中VP1阳性者HLA-I高表达频率45.8%高于VP1阴性者16%(p<0.001)。组织学研究不能证明因果关系,数据支持肠道病毒感染可能贯穿1型糖尿病自然史并驱动HLA-I高表达的假说。
要点
- T1D-ICI供者胰岛VP1阳性率77.5%,高于ND供者38.2%(p<0.001)。
- 所有供者中VP1阳性者HLA-I高表达频率45.8%,高于VP1阴性者16%(p<0.001)。
- 首次显示临床前自身抗体阳性阶段即同时存在VP1阳性和HLA-I高表达。
核心结论
- VP1与诊断后残留β细胞相关,自身抗体阳性临床前阶段即可检测到VP1阳性。
- 首次显示临床前阶段胰岛细胞同时存在VP1阳性和HLA-I高表达。
- 组织学研究不能证明因果关系,数据支持肠道病毒感染可能贯穿1型糖尿病自然史并可能是驱动HLA-I高表达的多种机制之一。
研究设计与样本
- nPOD收集188例器官捐献者胰腺、脾、十二指肠和胰腺淋巴结组织。
- 分组:无糖尿病供者ND n=76,单一或多重糖尿病相关自身抗体阳性供者AAb+ n=20、AAb++ n=9,1型糖尿病含残留胰岛素胰岛供者T1D-ICI n=41,仅胰岛素缺乏胰岛供者T1D-IDI n=42。
- 两个独立实验室用免疫组化评估VP1,用免疫组化和免疫荧光评估HLA-I,确定实验室间检测一致性和阳性检测总体发生率。
主要发现
- T1D-ICI供者胰岛细胞VP1阳性率77.5%,ND供者38.2%(p<0.001)。
- 评估HLA-I和VP1的供者中73.7%同时有VP1免疫阳性和HLA-I高表达(p<0.001 vs ND)。
- HLA-I高表达供者中VP1+细胞检出频率更高(p<0.001 vs HLA-I正常)。
- VP1+供者中AAb++和T1D-ICI组HLA-I高表达比例显著更高(94.9%,p<0.001 vs ND),不限于新发糖尿病个体。
- 所有供者合并分析,VP1+供者HLA-I高表达频率45.8%,VP1-供者16%(p<0.001)。
局限性
- 组织学研究不能证明因果关系。
- 数据支持假说而非确立因果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Earlier studies of pancreases from donors with type 1 diabetes demonstrated enteroviral capsid protein VP1 in beta cells. In the context of a multidisciplinary approach undertaken by the nPOD-Virus group, we assessed VP1 positivity in pancreas and other tissues (spleen, duodenum and pancreatic lymph nodes) from 188 organ donors, including donors with type 1 diabetes and donors expressing autoantibody risk markers. We also investigated whether VP1 positivity is linked to the hyperexpression of HLA class I (HLA-I) molecules in islet cells. METHODS: Organ donor tissues were collected by the Network for Pancreatic Organ Donors with Diabetes (nPOD) from donors without diabetes (ND, n=76), donors expressing a single or multiple diabetes-associated autoantibodies (AAb+, n=20; AAb++, n=9) and donors with type 1 diabetes with residual insulin-containing islets (T1D-ICIs, n=41) or only insulin-deficient islets (T1D-IDIs, n=42). VP1 was assessed using immunohistochemistry (IHC) and HLA-I using IHC and immunofluorescence, in two independent laboratories. We determined assay concordance across laboratories and overall occurrence of positive assays, on a case-by-case basis and between donor groups. RESULTS: Islet cell VP1 positivity was detected in most T1D-ICI donors (77.5%) vs only 38.2% of ND donors (p<0.001). VP1 positivity was associated with HLA-I hyperexpression. Of those donors assessed for HLA-I and VP1, 73.7% had both VP1 immunopositivity and HLA-I hyperexpression (p<0.001 vs ND). Moreover, VP1+ cells were detected at higher frequency in donors with HLA-I hyperexpression (p<0.001 vs normal HLA-I). Among VP1+ donors, the proportion with HLA-I hyperexpression was significantly higher in the AAb++ and T1D-ICI groups (94.9%, p<0.001 vs ND); this was not restricted to individuals with recent-onset diabetes. Critically, for all donor groups combined, HLA-I hyperexpression occurred more frequently in VP1+ compared with VP1- donors (45.8% vs 16%, p<0.001). CONCLUSIONS/INTERPRETATION: We report the most extensive analysis to date of VP1 and HLA-I in pancreases from donors with preclinical and diagnosed type 1 diabetes. We find an association of VP1 with residual beta cells after diagnosis and demonstrate VP1 positivity during the autoantibody-positive preclinical stage. For the first time, we show that VP1 positivity and HLA-I hyperexpression in islet cells are both present during the preclinical stage. While the study of tissues does not allow us to demonstrate causality, our data support the hypothesis that enterovirus infections may occur throughout the natural history of type 1 diabetes and may be one of multiple mechanisms driving islet cell HLA-I hyperexpression.
引用
- Rodriguez-Calvo T, Laiho JE, Oikarinen M, et al. Enterovirus VP1 protein and HLA class I hyperexpression in pancreatic islet cells of organ donors with type 1 diabetes. Diabetologia. 2025. PMID: 40090995. doi:10.1007/s00125-025-06384-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。